Current overview of the diagnosis and treatment of cancer of the stomach
Authors:
J. Gatěk 1
; L. Petruželka 2
Authors place of work:
Chirurgické oddělení nemocnice Atlas, Univerzita Tomáše Bati ve Zlíně
Primář: MUDr. Jiří Gatěk, Ph. D.
1; Onkologická klinika 1. LF UK a VFN, Praha
Přednosta: prof. MUDr. Luboš Petruželka, CSc.
2
Published in the journal:
Prakt. Lék. 2009; 89(4): 178-184
Category:
Reviews
Summary
Although the incidence of stomach cancer has fallen recently, it still remains a substantial problem. No new diagnostic method has enabled diagnosis in the early stages of cancer. Diagnosis is confirmed by an endoscope, and this, in conjunction with supplementary tests, can determine the stage of the disease. Surgical removal of the tumour is the treatment method of choice. Care is taken to ensure that the tumour is also completed removed from the lymph nodes. Surgery has limited impact in advanced stage cancer and prognosis is generally unfavourable. Neither radiotherapy nor chemotherapy is able to currently affect the course of the disease.
Key words:
stomach cancer, diagnosis, surgery, adjuvant therapy.
Zdroje
1. Bozzetti, F., Marubini, E., Bonfanti, G. et al. Subtotal versus total gastrectomy for gastric cancer: five surfoval rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann. Surg. 1999, 230, p. 170-178.
2. Hundahl, S.A., Phillips, J.L., Menck, H.R. The National Cancer Data Base Report on poor survival of US gastric carcinoma patients treated with gastrectomy: fifth edition American Joint Committee on Cancer staging, proximal disease, and the different disease, hypothesis. Cancer 2000, 88, p. 921-932.
3. La Vecchia, C., Negri, E., Franceschi, S. et al. Family history and the risk of stomach and colorectal cancer. Cancer 1993, 71, p. 1731-1735.
4. Lauren, T. The two histological main types of gastric carcinoma. Acta Pathol. Microbiol. Scand. 1965, 64, p. 34.
5. Werner, M., Becker, K., Keller, G. et al. Gastric adenocarcinoma: pathomorphology and molecular pathology. J. Cancer Res. Clin. Oncol. 2001, 127, p. 207-216.
6. Angelelli, G., Ianora, A.A., Scardapane, A. et al. Role of computerized tomography in the staging of gastrointestinal neoplasms. Semin. Surg. Oncol. 2001, 20, p. 109-121.
7. Harrison, L.E., Karpeh, M.S., Brennan, M.F. Total gastrectomy is not necessary for proximal gastric cancer. Surgery 1998, 123, p. 127-130.
8. Heberer, G., Teichmann, R.K., Kramling, H.J. et al. Results of gastric resection for carcinoma of the stomach: the European experience. World J. Surg. 1988, 12, p. 374-381.
9. Bozzetti, F. Principles of surgical radicality in the treatment of gastric cancer. Surg. Oncol. Clin. North Am. 2001, 10, p. 833-854.
10. Bonenkamp, J., Songun, I., Hermans J. et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in Dutch patients. Lancet 1995, 345, p. 745-748.
11. Abe, N., Watanabe, T., Suzuki, K. et al Risk factor of lymph node metastation in depressed early gastric cancer. Am. J. Surg. 2002, 183, p. 168-172.
12. Maruyama, K., Okabayashi, K., Kinoshita, T. Progress in gastric cancer surgery in Japan and its limits of radicality. World J. Surg. 1987, 11, p. 418-425.
13. Bonenkamp, J.J., Hermans, J., Sasako, M. et al. Extended lymph-node dissection for gastric cancer. Dutch Gastric Cancer Group. N. Engl. J. Med. 1999, 340, p. 908-914.
14. Siewert, J.R., Bottcher, K., Stein, H.J. et al. Relevant prognóztic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann. Surg. 1998, 228, p. 449-461.
15. Cuschieri, A., Weeden, S., Fielding, J. et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br. J. Cancer 1999, 79, p. 1522-1530.
16. Siewert, R., Bottchter, K., Stein, H., Jurgen, R. Relevant prognostic factor in gastric cancer ten-years result of the German Gastric Cancer Study. Ann. Surg. 1998, 228, p. 449-461.
17. Popiela, T., Kulig, J., Kolodziejczyk, P. et al. Long-term results of surgery for early gastric cancer. Br. J. Surg. 2002, 89, p. 1035-1042.
18. Karpeh, M.S., Leon, L., Klimstra, D. et al. Lymph node staging in gastric cancer: is location more important than number? An analysis of 1038 patients. Ann. Surg. 2000, 232, p. 362-371.
19.Chen, S., Bilchnik, A. More extensive nodal dissection improves survival for stages I to III of colon cancer a population-based study. Ann. Surg. 2006, 244, p. 602-610.
20. Schwartz, G., Giuliano, A., Veronesi, U. et al. Proceedings of the Consensus Conference on the Role of Sentinel Lymph Node Biopsy in Carcinoma of the Breast April 19-22, 2001 Philadelphia Pennsylvania. Cancer 2002, 94, p. 2542 -2551.
21. Kitagawa, Y., Fujii, H., Mukai, M. et al. Radio-guided sentinel node detection for gastric cancer. Br. J. Surg. 2002, 89, p. 604-608.
22. Miwa, K., Kinami, S., Taniguchi, K. et al. Mapping sentinel nodes in patients with early-stage gastric carcinoma. Br. J. Surg. 2003, 90, p. 178-182.
23. Gretschel, S., Bembenek, A., Ulmer, Ch. et al. Lymphatic mapping und Sentinel-Lympknotendiagnostik beim Magenkarcinom. Chirurg 2003, 74, s. 132-138.
24. Kim, M., Kim, H., Jung, G. et al. Lymphatic mapping and sentinel node biopsy using 99mTC colloid in gastric cancer. Ann Surg 2004; 239: p. 383-387.
25. Hiratsuka, M., Miyashiro, I., Ishikawa, H. et al. Application of sentinel node biopsy to gastric cancer surgery. Surgery 2001, 71, p. 335-340.
26. Šimša, J., Leffler, J., Schwarz, J. a kol. Karcinom žaludku – koncept sentinelové uzliny: první zkušenosti. Rozhl. Chir. 2002, 81, p. 312-315.
27. Gatěk, J., Duben, J., Bakala, J. a kol. Lymfadenektomie u časného karcinomu žaludku. Rozhl. Chir. 2004, 83, p. 428-435.
28. Fukagawa, T., Sasaco, M., Mann, G. Immunohistochemically detected micrometastasis of the lymph nodes in patients with gastric carcinoma. Cancer 2001, 92, p. 753-760.
29. Macdonald, J.S., Smalley, S.R., Benedetti, J. et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. 2001, 345, p. 725-730.
30. Hermans, J., Bonenkamp, J.J., Boon, M.C. et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J. Clin. Oncol. 1993, 11, p. 1441-1447.
31 Earle, C.C., Maroun, J.A. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur. J. Cancer 1999, 35, p. 1059-1064.
32. Mari, E., Floriani, I., Tinazzi, A. et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente). Ann. Oncol. 2000, 1, p. 837-843.
33. Panzini, I., Gianni, L., Fattori, P.P. et al. Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori 2002, 88, p. 21-27.
34. Pyrhönen, S., Kuitunen, T., Nyandoto, P. et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br. J. Cancer 1995, 71, p. 587-591.
35. Murad, A.M., Santiago, F.F., Petroianu, A. et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993, 72, p. 37-41.
36. Gimelius, B., Hoffman, K., Haglund, U. et al. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann. Oncol. 1994, 5, p. 189-190.
37. MacDonald, J.S., Schein, P.S., Woolley, P.V. et al. Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann. In.t Med. 1980, 93, p. 533-536.
38. Al-Batran, S.E., Atmaca, A., Hegewisch-Becker, S. et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J. Clin. Oncol. 2004, 22, p. 658-663.
39. Tsuji, S., Tsujii, M. COX-2 and advanced digestive cancer phenotypes. J. Gastr. 2004, 39, p. 1224-1225.
40. Louvet, L., Tigaud, J.M., Gamelin, E. et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J. Clin. Oncol. 2002, 20, p. 4543-4548.
41. Sumpter, K., Harper-Wynne, C., Cunningham, D. et al. Oxaliplatin and capecitabine chemotherapy for advanced colorectal cancer: a single institution’s experience. Clin. Oncol. 2003, 15, p. 221-226.
42. Moehler, M., Haas, U., Siebler, J. et al. Weekly treatment with irinotecan, folinic acid and infusional 5-fluorouracil (ILF) in patients with advanced gastric cancer. Anticancer Drugs 2003, 14, p. 645-650.
Štítky
General practitioner for children and adolescents General practitioner for adultsČlánok vyšiel v časopise
General Practitioner
2009 Číslo 4
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Memantine Eases Daily Life for Patients and Caregivers
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
Najčítanejšie v tomto čísle
- Lichen sclerosus
- Detection of latent tuberculosis, QuantiFERON-TB Gold test, possibilities and pitfalls of the method
- Microvascular decompression of cranial nerves – effect and risk of treatment
- Current overview of the diagnosis and treatment of cancer of the stomach